GeoVax Labs Eyes Fast-Track Phase 3 Trial for Mpox Vaccine as Funding Push Continues

GeoVax Labs (NASDAQ:GOVX) Chairman and CEO David Dodd said the clinical-stage biotechnology company is preparing to advance its lead vaccine program, GEO-MVA, into a pivotal Phase 3 trial under an expedited European regulatory pathway. Speaking during a Tribe Public webinar hosted by John Heerdink, managing member of Tribe Public, Dodd described GeoVax’s priority program as [...]